已收盤 03-26 16:00:00 美东时间
0.000
0.00%
This order adds to the U.S. Army's growing adoption of the eBee VISION platform. The U.S. Army has now ordered thirty-four eBee VISION unmanned systems across six distinct organizations. Notable recent acquisitions
05-05 20:12
Governments are accelerating investments in scalable autonomous drone operations without the burden of fleet ownership Market News Updates News Commentary Counter NEW YORK, April 23, 2026 /P...
04-23 21:00
AgEagle stock rises after $10M investment and new counter-drone joint venture, signaling expansion into defense markets.
04-14 23:04
AgEagle Aerial Systems (UAVS) said on Tuesday its subsidiary EagleNXT had formed a U.S.-based joint venture, ThirdEye USA, with Israel’s ThirdEye Systems, alongside a $10M strategic investment. The v...
04-14 19:54
The new U.S.-based entity will provide a line of counter-drone products and systems to the U.S. and Canadian markets, and will operate out of EagleNXT's headquarters in Allen, Texas. EagleNXT will own 51.0% of ThirdEye
04-14 19:24
Advanced AI, automation, and data analytics push DaaS into the mainstream across key industries Market News Updates News Commentary Counter NEW YORK, April 9, 2026 /PRNewswire/ -- The Drone-...
04-09 21:40
Order reflects continued adoption of Blue UAS-listed platform across allied operational environmentsALLEN, Texas, April 06, 2026 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (dba, EagleNXT) (the "Company" or
04-06 20:04
AgEagle Aerial Systems Inc. (EagleNXT) announced the sale of 15 eBee VISION unmanned aerial systems to a U.S. Army unit in Europe. The eBee VISION, a Blue UAS-listed ISR platform, offers real-time HD and thermal video, long-endurance flight, and secure architecture. The transaction was facilitated by Dronivo GmbH. This order highlights the growing adoption of the eBee VISION in defense and security missions globally, enhancing allied readiness fo...
04-06 12:00
AgEagle Aerial Systems press release (UAVS): FY Net loss improved significantly to $(5.3) million as compared to $(35.0) million for the year ended December 31, 2024, a reduction of $29.7 million, or ...
04-01 04:28
Serina Therapeutics reported financial results for 2025, highlighting FDA clearance for SER-252, initiation of its Phase 1b trial, and a $30 million private placement financing. The company achieved operating expenses of $24.2 million, net loss of $19.4 million, and ended with $3.1 million in cash. Key milestones include advancing SER-252 for Parkinson's disease, securing new funding, and strengthening the balance sheet for upcoming clinical tria...
03-25 20:20